Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes A Secondary Analysis of the PLATO Biomarker Study

被引:62
作者
Lindholm, Daniel [1 ,2 ]
James, Stefan K. [1 ,2 ]
Gabrysch, Katja [2 ]
Storey, Robert F. [3 ]
Himmelmann, Anders [4 ]
Cannon, Christopher P. [5 ,6 ]
Mahaffey, Kenneth W. [7 ]
Steg, Philippe Gabriel [8 ,9 ,10 ]
Held, Claes [1 ,2 ]
Siegbahn, Agneta [2 ,11 ]
Wallentin, Lars [1 ,2 ]
机构
[1] Uppsala Univ, Dept Med Sci, Cardiol, Uppsala, Sweden
[2] Uppsala Clin Res Ctr, Dag Hammarskjolds Vag 38, SE-75185 Uppsala, Sweden
[3] Univ Sheffield, Dept Cardiovasc Sci, Sheffield, S Yorkshire, England
[4] AstraZeneca Res & Dev, Molndal, Sweden
[5] Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA
[6] Baim Clin Res Inst, Boston, MA USA
[7] Stanford Sch Med, Stanford Ctr Clin Res, Stanford, CA USA
[8] Dept Hosp Univ FIRE, Hop Bichat, AP HP, Paris, France
[9] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France
[10] Royal Brompton Hosp, ICMS, NHLI Imperial Coll, London, England
[11] Uppsala Univ, Dept Med Sci, Clin Chem, Uppsala, Sweden
关键词
DIFFERENTIATION FACTOR 15; BRAIN NATRIURETIC PEPTIDE; PROGNOSTIC VALUE; TROPONIN-T; CLOPIDOGREL; RECEPTOR; TICAGRELOR; OUTCOMES; GDF15; REVASCULARIZATION;
D O I
10.1001/jamacardio.2018.3811
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Mortality remains at about 5% within a year after an acute coronary syndrome event. Prior studies have assessed biomarkers in relation to all-cause or cardiovascular deaths but not across multiple causes. OBJECTIVE To assess if different biomarkers provide information about the risk for all-cause and cause-specific mortality. DESIGN, SETTING, AND PARTICIPANTS The Platelet Inhibition and Patient Outcomes (PLATO) trial randomized 18 624 patients with acute coronary syndrome to ticagrelor or clopidogrel from October 2006 through July 2008. In this secondary analysis biomarker substudy, 17 095 patients participated. MAIN OUTCOMES AND MEASURES Death due to myocardial infarction, heart failure, sudden cardiac death/arrhythmia, bleeding, procedures, other vascular causes, and nonvascular causes, as well as all-cause death. EXPOSURES At baseline, levels of cystatin-C, growth differentiation factor-15 (GDF-15), high-sensitivity C-reactive protein, high-sensitivity troponin I and T, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were determined. RESULTS The median (interquartile range) age of patients was 62.0 (54.0-71.0) years. Of 17 095 patients, 782 (4.6%) died during follow-up. The continuous associations between biomarkers and all-cause and cause-specific mortality were modeled using Cox models and presented as hazard ratio (HR) comparing the upper vs lower quartile. For all-cause mortality, NT-proBNP and GDF-15 were the strongest markers with adjusted HRs of 2.96 (95% CI, 2.33-3.76) and 2.65 (95% CI, 2.17-3.24), respectively. Concerning death due to heart failure, NT-proBNP was associated with an 8-fold and C-reactive protein, GDF-15, and cystatin-C, with a 3-fold increase in risk. Regarding sudden cardiac death/arrhythmia, NT-proBNP was associated with a 4-fold increased risk and GDF-15 with a doubling in risk. Growth differentiation factor-15 had the strongest associations with other vascular and nonvascular deaths and was possibly associated with death due to major bleeding (HR, 4.91; 95% CI, 1.39-17.43). CONCLUSIONS AND RELEVANCE In patients with acute coronary syndrome, baseline levels of NT-proBNP and GDF-15 were strong markers associated with all-cause death based on their associations with death due to heart failure as well as due to arrhythmia and sudden cardiac death. Growth differentiation factor-15 had the strongest associations with death due to other vascular or nonvascular causes and possibly with death due to bleeding.
引用
收藏
页码:1160 / 1166
页数:7
相关论文
共 33 条
[1]  
[Anonymous], 2000, JAMA, V284, P3043
[2]   N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease [J].
Bibbins-Domingo, Kirsten ;
Gupta, Reena ;
Na, Beeya ;
Wu, Alan H. B. ;
Schiller, Nelson B. ;
Whooley, Mary A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (02) :169-176
[3]   Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction [J].
Björklund, E ;
Jernberg, T ;
Johanson, P ;
Venge, P ;
Dellborg, M ;
Wallentin, L ;
Lindahl, B .
HEART, 2006, 92 (06) :735-740
[4]   Growth Differentiation Factor-15 Deficiency Inhibits Atherosclerosis Progression by Regulating Interleukin-6-Dependent Inflammatory Response to Vascular Injury [J].
Bonaterra, Gabriel A. ;
Zuegel, Stefanie ;
Thogersen, Joel ;
Walter, Sabrina A. ;
Haberkorn, Uwe ;
Strelau, Jens ;
Kinscherf, Ralf .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2012, 1 (06) :e002550
[5]   The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes [J].
de Lemos, JA ;
Morrow, DA ;
Bentley, JH ;
Omland, T ;
Sabatine, MS ;
McCabe, CH ;
Hall, C ;
Cannon, CP ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (14) :1014-1021
[6]   Change in Growth Differentiation Factor 15 Concentrations over Time Independently Predicts Mortality in Community-Dwelling Elderly Individuals [J].
Eggers, Kai M. ;
Kempf, Tibor ;
Wallentin, Lars ;
Wollert, Kai C. ;
Lind, Lars .
CLINICAL CHEMISTRY, 2013, 59 (07) :1091-1098
[7]   The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL [J].
Emmerson, Paul J. ;
Wang, Feng ;
Du, Yong ;
Liu, Qian ;
Pickard, Richard T. ;
Gonciarz, Malgorzata D. ;
Coskun, Tamer ;
Hamang, Matthew J. ;
Sindelar, Dana K. ;
Ballman, Kimberly K. ;
Foltz, Lisa A. ;
Muppidi, Avinash ;
Alsina-Fernandez, Jorge ;
Barnard, Gavin C. ;
Tang, Jason X. ;
Liu, Xilin ;
Mao, Xudong ;
Siegel, Robert ;
Sloan, John H. ;
Mitchell, Pamela J. ;
Zhang, Bei B. ;
Gimeno, Ruth E. ;
Shan, Bei ;
Wu, Xinle .
NATURE MEDICINE, 2017, 23 (10) :1215-+
[8]   Growth Differentiation Factor 15 Predicts AM-Cause Morbidity and Mortality in Stable Coronary Heart Disease [J].
Hagstrom, Emil ;
Held, Claes ;
Stewart, Ralph A. H. ;
Aylward, Philip E. ;
Budaj, Andrzej ;
Cannon, Christopher P. ;
Koenig, Wolfgang ;
Krug-Gourley, Sue ;
Mohler, Emile R., III ;
Steg, Philippe Gabriel ;
Tarka, Elizabeth ;
Ostlund, Ollie ;
White, Harvey D. ;
Siegbahn, Agneta ;
Wallentin, Lars .
CLINICAL CHEMISTRY, 2017, 63 (01) :325-333
[9]   Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study [J].
Hagstrom, Emil ;
James, Stefan K. ;
Bertilsson, Maria ;
Becker, Richard C. ;
Himmelmann, Anders ;
Husted, Steen ;
Katus, Hugo A. ;
Steg, Philippe Gabriel ;
Storey, Robert F. ;
Siegbahn, Agneta ;
Wallentin, Lars .
EUROPEAN HEART JOURNAL, 2016, 37 (16) :1325-1333
[10]   Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial [J].
Hijazi, Ziad ;
Oldgren, Jonas ;
Andersson, Ulrika ;
Connolly, Stuart J. ;
Eikelboom, EJohn W. ;
Ezekowitz, Michael D. ;
Reilly, Paul A. ;
Yusuf, Salim ;
Siegbahn, Agneta ;
Wallentin, Lars .
AMERICAN HEART JOURNAL, 2017, 190 :94-103